Cardinal Health Inc. CAH reported first-quarter fiscal 2017 adjusted earnings of $1.24 per share, which beat the Zacks Consensus Estimate of $1.21 but decreased 10% on a year-over-year basis.
The earnings beat was driven by 14% growth in revenues, which totaled $32.0 billion and surpassed the Zacks Consensus Estimate of $31.2 billion. The revenue growth was on account of strong performance by both the Pharmaceutical and Medical segments.
Pharmaceutical revenues increased 14% to $28.8 billion owing to strong growth from existing and net new distribution customers. Strong performance from the Specialty business also drove results.
Medical segment revenues increased 12% to $3.3 billion. Higher contributions from acquisitions and net new and existing customers were primarily behind the growth in Medical segment revenues.
Distribution, selling, general and administrative (SG&A) expenses increased 9% on a year-over-year basis to $920 million in the reported quarter.
Pharmaceutical segment profit in the quarter decreased 19% to $534 million due to generic pharmaceutical pricing and reduced levels of branded inflation. This was partially offset by solid performance by Red Oak Sourcing.
Medical segment profit soared 26% to $127 million on the back of strong contribution from acquisitions and the Cardinal Health Brand products.
In the reported quarter, net income declined 19% to $309 million from last fiscal year's $383 million. Adjusted net income was $399 million compared with $458 million in the year-ago period.
CARDINAL HEALTH Price, Consensus and EPS Surprise
CARDINAL HEALTH Price, Consensus and EPS Surprise | CARDINAL HEALTH Quote
Based on fiscal first-quarter results and second-quarter expectations, the company lowered its fiscal 2017 guidance range for adjusted earnings per share from continuing operations to $5.40 to $5.60 from $5.48 to $5.73. The outlook represents growth of approximately 3% to 7% from the prior fiscal year.
Full-fiscal Pharmaceutical segment profit is now expected to be lower than fiscal 2016. The downside would come from generic pharmaceutical pricing and, to a lesser extent, from reduced levels of branded inflation.
Zacks Rank & Stocks to Consider
Currently, Cardinal Health carries a Zacks Rank #4 (Sell).
Better-ranked stocks in the broader medical sector are Intuitive Surgical Inc. ISRG, AngioDynamics Inc. ANGO and Glaukos Corporation GKOS. Notably, AngioDynamics and Intuitive Surgical carry a Zacks Rank #2 (Buy) while Glaukos sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Intuitive Surgical has a long-term expected earnings growth rate of approximately 11.35%. The stock represents an impressive one-year return of approximately 32.2%.
AngioDynamics has a long-term expected earnings growth rate of 15.00%. The company posted a solid one-year return of almost 21.8%.
Glaukos Corporation recorded a stellar one-year return of almost 66.09%. Notably, the company posted positive surprises in the past four quarters, the average being 110.93%.
Confidential from Zacks
Beyond this Analyst Blog, would you like to see Zacks' best recommendations that are not available to the public? Our Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand. Click to see them now>>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
INTUITIVE SURG (ISRG): Free Stock Analysis Report
ANGIODYNAMICS (ANGO): Free Stock Analysis Report
CARDINAL HEALTH (CAH): Free Stock Analysis Report
GLAUKOS CORP (GKOS): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research